Literature DB >> 3279140

Comparison of immunoblotting and indirect enzyme-linked immunosorbent assay using different antigen preparations for diagnosing early Lyme disease.

R L Grodzicki1, A C Steere.   

Abstract

We compared immunoblotting and indirect enzyme-linked immunosorbent assay (ELISA) using different antigen preparations to test for antibody to Borrelia burgdorferi in patients with early Lyme disease. With immunoblotting, 16 (53%) of 30 patients had positive tests in acute-phase sera and 25 (83%) had them in convalescent-phase sera. Among 64 controls, false-positive results were obtained in only three individuals with syphilis and in one hospitalized patient with renal allograft rejection. Among the patients with Lyme disease, both IgM and IgG antibodies most commonly bound to the 41-kilodalton (kDa) flagellar antigen, but many patients had binding to other components, particularly those of 25, 55, 58, or 66 kDa, and the order of their appearance was variable. Compared with indirect ELISA (using sonicated whole spirochetes or a flagellin-enriched fraction as the antigen preparation), more patients with Lyme disease had positive tests by immunoblotting, and fewer control subjects had false-positive results. Our results indicate that immunoblotting is superior to indirect ELISA for diagnosing early Lyme disease.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3279140     DOI: 10.1093/infdis/157.4.790

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  82 in total

1.  Chlamydial serology: comparative diagnostic value of immunoblotting, microimmunofluorescence test, and immunoassays using different recombinant proteins as antigens.

Authors:  S Bas; P Muzzin; B Ninet; J E Bornand; C Scieux; T L Vischer
Journal:  J Clin Microbiol       Date:  2001-04       Impact factor: 5.948

2.  Intra- and interlaboratory reproducibility of an ELISA serological test for Lyme disease.

Authors:  M C Tammemagi; J W Frank; M Leblanc; H Artsob
Journal:  Can J Infect Dis       Date:  1995-03

3.  Comparative evaluation of three products for the detection of Borrelia burgdorferi antibody in human serum.

Authors:  R D Fister; L A Weymouth; J C McLaughlin; R W Ryan; R C Tilton
Journal:  J Clin Microbiol       Date:  1989-12       Impact factor: 5.948

4.  Further characterization of a potent immunogen and the chromosomal gene encoding it in the Lyme disease agent, Borrelia burgdorferi.

Authors:  G C Perng; R B LeFebvre; R C Johnson
Journal:  Infect Immun       Date:  1991-06       Impact factor: 3.441

5.  Mapping antibody-binding domains of the major outer surface membrane protein (OspA) of Borrelia burgdorferi.

Authors:  W H Schubach; S Mudri; R J Dattwyler; B J Luft
Journal:  Infect Immun       Date:  1991-06       Impact factor: 3.441

6.  Ovalbumin blocking improves sensitivity and specificity of immunoglobulin M immunoblotting for serodiagnosis of patients with erythema migrans.

Authors:  R Lange; H Bocklage; T Schneider; H W Kölmel; J Heesemann; H Karch
Journal:  J Clin Microbiol       Date:  1992-01       Impact factor: 5.948

7.  Comparison of Western blot and enzyme-linked immunosorbent assay for diagnosis of Lyme borreliosis.

Authors:  M Karlsson; I Möllegård; G Stiernstedt; B Wretlind
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-10       Impact factor: 3.267

8.  Serologic analyses of cottontail rabbits for antibodies to Borrelia burgdorferi.

Authors:  L A Magnarelli; J F Anderson; J B McAninch
Journal:  J Clin Microbiol       Date:  1990-05       Impact factor: 5.948

9.  Expression of public idiotypes in patients with Lyme arthritis.

Authors:  J S Axford; R A Watts; A A Long; D A Isenberg; A C Steere
Journal:  Ann Rheum Dis       Date:  1993-03       Impact factor: 19.103

10.  Molecular and immunological characterization of a novel polymorphic lipoprotein of Borrelia burgdorferi.

Authors:  R Wallich; M M Simon; H Hofmann; S E Moter; U E Schaible; M D Kramer
Journal:  Infect Immun       Date:  1993-10       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.